menu
    • menu

    Find Trastuzumab manufacturers, exporters & distributors on PharmaCompass

    LGM Trastuzumab

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    12

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    1

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    9

    Listed Suppliers

    Other Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    161

    FDF Dossiers

    FDF Dossiers

    11

    FDA Orange Book

    FDA (Orange Book)

    8

    Europe

    Europe

    15

    Canada

    Canada

    118

    Australia

    Australia

    6

    South Africa

    South Africa

    3

    Listed Dossiers

    Listed Dossiers

    100DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    6RELATED EXCIPIENT COMPANIES

    14EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    8

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 3,808,443

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    51,759

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    4

    API

    10

    FDF

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    1

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    316

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set

    Listed Suppliers

    read-more
    read-more

    01

    LGM Pharma

    U.S.A
    arrow
    ChemOutsourcing
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Trastuzumab

    About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

    LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Shanghai Minbiotech

    China
    arrow
    CPhI China
    Booth #W3G18
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Trastuzumab

    About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

    ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Beijing Mesochem Technology

    China
    arrow
    CPhI China
    Booth #W4Q37
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMesochem is focused on incessant innovation along with the R&D of new APIs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Trastuzumab

    About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...

    Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine chemicals and fundamental chemical materials. It has an efficient research and development team. Beijing Mesochem provides its customers customized development, craft optimization, contract customization and outsourcing services. The company has a well-established industrial base in Weinan, Shanxi Province. The production base features a 20,000 ㎡ plant with a production capacity of over 8,000 MT per year.
    Mesochem Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Biotechnica DWC

    Algeria
    FCE Pharma
    Not Confirmed
    arrow

    Biotechnica DWC

    Algeria
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Algeria
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Trastuzumab

    About the Company : BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies al...

    BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies all over the world. Biotechnica is an integrated global solution provider from design to implementation of industrial projects in the areas of Pharmaceuticals,Agri-food ,Cosmetics and Nutrition. With more than 25 years of experience in the assembly of plants, particularly in the pharmaceutical sector, we accompany our customers in the various stages of their projects – E-CTD Dossieers – Raw Materiels – Equipements – Accessories – Packaging – Distribution.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Conscientia Industrial

    China
    FCE Pharma
    Not Confirmed
    arrow

    Conscientia Industrial

    China
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Trastuzumab

    About the Company : Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We...

    Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We started business in early 2010, producing and providing products for both human and veterinary health at home and abroad. Conscientia Industrial makes regular productions and also provides custom synthesis, contract manufacturing services. We have series of products, such as Hormones, Prostaglandins, Peptides, Anti-cancer, Anti-tumor, Anti-virus, Anti-diabetic APIs and their related intermediates, impurities, chemicals.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Delphis Pharmaceutical India

    India
    FCE Pharma
    Not Confirmed
    arrow

    Delphis Pharmaceutical India

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Trastuzumab

    About the Company : The last few years have seen dramatic growth in outsourcing to India in all areas of technology. The trend has been particularly noticeable in the pharmaceuticals sector. Leading p...

    The last few years have seen dramatic growth in outsourcing to India in all areas of technology. The trend has been particularly noticeable in the pharmaceuticals sector. Leading pharmaceutical firms across the world are increasingly turning to India to outsource processes and solutions as part of their efforts to bring down the price of drugs. Drug makers operating in US could save at least 60 per cent in producing new drugs by out sourcing R&D and other services to India; it is estimated. In this way, we come in to picture. DELPHIS PHARMA is pharma house which offers third-party manufacturing for domestic and export formulations.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    KinBio

    Israel
    FCE Pharma
    Not Confirmed
    arrow

    KinBio

    Israel
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Trastuzumab

    About the Company : KinBio is a rapidly growing biopharmaceutical company based in Rehovot, Israel, with its main focus on developing needed therapies as well as offering a wide range of CDMO services...

    KinBio is a rapidly growing biopharmaceutical company based in Rehovot, Israel, with its main focus on developing needed therapies as well as offering a wide range of CDMO services – from concept to product. KinBio’s main focus is to pursue opportunities in the global pharmaceutical market. Augmented by a global group of affiliated companies, Kinbio specializes in research, development, manufacturing and commercialization of biopharmaceutical products. Kinbio’s commitment to top standard quality is inherent across the entire global organization, from our FDA approved cGMP sites to our state of the art R&D laboratories.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Nanogen Pharmaceutical Biotechnolog...

    Vietnam
    FCE Pharma
    Not Confirmed
    arrow

    Nanogen Pharmaceutical Biotechnolog...

    Vietnam
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Vietnam
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Trastuzumab

    About the Company : Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are pro...

    Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are proud to be the leading company in the Asia-Pacific region that successfully researched and developed Active Pharmaceutical Ingredients (APIs) and specific therapeutic products on the foundation of advanced recombinant DNA/protein technology.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Nanogen Pharmaceutical Biotechnolog...

    Vietnam
    FCE Pharma
    Not Confirmed
    arrow

    Nanogen Pharmaceutical Biotechnolog...

    Vietnam
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Vietnam
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Trastuzumab

    About the Company : Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are pro...

    Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are proud to be the leading company in the Asia-Pacific region that successfully researched and developed Active Pharmaceutical Ingredients (APIs) and specific therapeutic products on the foundation of advanced recombinant DNA/protein technology.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644517800,"product":"TRASTUZUMAB(R-DNA ORIGIN)DRUG SUBSTANCE(","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DRREDDY\\'S LABORATORIES LTD","supplierCountry":"INDIA","foreign_port":"CHICAGO, IL","customer":"XERIS PHARMACEUTICALS","customerCountry":"UNITED STATES","quantity":"0.04","actualQuantity":"40","unit":"GMS","unitRateFc":"3895","totalValueFC":"152674.4","currency":"USD","unitRateINR":286100,"date":"11-Feb-2022","totalValueINR":"11444000","totalValueInUsd":"152674.4","indian_port":"HYDERABAD AIR","hs_no":"29379020","bill_no":"8157910","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1688322600,"product":"TRASTUZUMAB DRUG SUBSTANCE(QTY:5 GMS)(FO","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DRREDDY\\'S LABORATORIES LTD","supplierCountry":"INDIA","foreign_port":"LONDON - HEATHROW","customer":"DRREDDYS LABORATORIES LTD","customerCountry":"UNITED KINGDOM","quantity":"0.01","actualQuantity":"5","unit":"GMS","unitRateFc":"3286","totalValueFC":"16121.3","currency":"USD","unitRateINR":265000.0626,"date":"03-Jul-2023","totalValueINR":"1325000.313","totalValueInUsd":"16121.3","indian_port":"HYDERABAD AIR","hs_no":"29379020","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N, HYDERABAD","customerAddress":""}]
    11-Feb-2022
    03-Jul-2023
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    APHINITY 10-Year Data Show Perjeta Regimen Cuts Death Risk by 17% in HER2+

    Details:

    Perjeta (pertuzumab) is approved for use in combination with Herceptin and chemotherapy in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.


    Lead Product(s): Pertuzumab,Trastuzumab,Docetaxel

    Therapeutic Area: Oncology Brand Name: Perjeta

    Study Phase: Approved FDFProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 13, 2025

    blank

    01

    Genentech

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Genentech

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pertuzumab,Trastuzumab,Docetaxel

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    APHINITY 10-Year Data Show Perjeta Regimen Cuts Death Risk by 17% in HER2+

    Details : Perjeta (pertuzumab) is approved for use in combination with Herceptin and chemotherapy in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.

    Product Name : Perjeta

    Product Type : Antibody

    Upfront Cash : Inapplicable

    May 13, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    ENHERTU Plus THP Shows Benefit in High-Risk HER2+ Breast Cancer Trial

    Details:

    Enhertu (trastuzumab deruxtecan) is a HER2-directed antibody and topoisomerase inhibitor, being investigated for high-risk, locally advanced HER2 positive early-stage breast cancer. conjugate


    Lead Product(s): Trastuzumab Deruxtecan,Paclitaxel,Trastuzumab

    Therapeutic Area: Oncology Brand Name: Enhertu

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 07, 2025

    blank

    02

    AstraZeneca

    United Kingdom
    arrow
    Simposio AFI
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    Simposio AFI
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab Deruxtecan,Paclitaxel,Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    ENHERTU Plus THP Shows Benefit in High-Risk HER2+ Breast Cancer Trial

    Details : Enhertu (trastuzumab deruxtecan) is a HER2-directed antibody and topoisomerase inhibitor, being investigated for high-risk, locally advanced HER2 positive early-stage breast cancer. conjugate

    Product Name : Enhertu

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    May 07, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CHMP Supports EU Label Update for Phesgo for Out-of-Clinic Use

    Details:

    PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists and hyaluronidase, an endoglycosidase, indicated for HER2-positive breast cancer.


    Lead Product(s): Pertuzumab,Trastuzumab,Hyaluronidase

    Therapeutic Area: Oncology Brand Name: Phesgo

    Study Phase: Approved FDFProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 30, 2025

    blank

    03

    F. Hoffmann-La Roche

    Switzerland
    arrow
    Simposio AFI
    Not Confirmed

    F. Hoffmann-La Roche

    Switzerland
    arrow
    Simposio AFI
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pertuzumab,Trastuzumab,Hyaluronidase

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CHMP Supports EU Label Update for Phesgo for Out-of-Clinic Use

    Details : PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists and hyaluronidase, an endoglycosidase, indicated for HER2-positive breast cancer.

    Product Name : Phesgo

    Product Type : Antibody

    Upfront Cash : Inapplicable

    April 30, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CuraTeQ Biologics Receives Positive Opinion for Biosimilar Dazublys from EMA

    Details:

    Dazublys is a trastuzumab biosimilar (HER2 inhibitor), indicated for the treatment of HER2-positive metastatic and early breast cancers.


    Lead Product(s): Trastuzumab

    Therapeutic Area: Oncology Brand Name: Dazublys

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 28, 2025

    blank

    04

    CuraTeQ Biologics

    India
    arrow
    Simposio AFI
    Not Confirmed

    CuraTeQ Biologics

    India
    arrow
    Simposio AFI
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CuraTeQ Biologics Receives Positive Opinion for Biosimilar Dazublys from EMA

    Details : Dazublys is a trastuzumab biosimilar (HER2 inhibitor), indicated for the treatment of HER2-positive metastatic and early breast cancers.

    Product Name : Dazublys

    Product Type : Antibody

    Upfront Cash : Inapplicable

    April 28, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    EMA Validates Henlius and Organon Filing for Perjeta Biosimilar HLX11

    Details:

    HLX11 (pertuzumab) is a HER2/neu receptor antagonist indicated in combination with rastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.


    Lead Product(s): Pertuzumab,Trastuzumab,Docetaxel

    Therapeutic Area: Oncology Brand Name: HLX11

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 28, 2025

    blank

    05

    Shanghai Henlius Biotech

    China
    arrow
    Simposio AFI
    Not Confirmed

    Shanghai Henlius Biotech

    China
    arrow
    Simposio AFI
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pertuzumab,Trastuzumab,Docetaxel

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    EMA Validates Henlius and Organon Filing for Perjeta Biosimilar HLX11

    Details : HLX11 (pertuzumab) is a HER2/neu receptor antagonist indicated in combination with rastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

    Product Name : HLX11

    Product Type : Antibody

    Upfront Cash : Inapplicable

    March 28, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Alligator Bioscience Gets FDA Orphan Drug Status for HLX22 in Gastric Cancer

    Details:

    HLX22 is a recombinant humanized Anti-HER2 mAb, being investigated in combination with SoC for HER2-positive advanced gastric/gastroesophageal junction cancer.


    Lead Product(s): HLX22,Oxaliplatin,Trastuzumab

    Therapeutic Area: Oncology Brand Name: HLX22

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 20, 2025

    blank

    06

    Shanghai Henlius Biotech

    China
    arrow
    Simposio AFI
    Not Confirmed

    Shanghai Henlius Biotech

    China
    arrow
    Simposio AFI
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : HLX22,Oxaliplatin,Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Alligator Bioscience Gets FDA Orphan Drug Status for HLX22 in Gastric Cancer

    Details : HLX22 is a recombinant humanized Anti-HER2 mAb, being investigated in combination with SoC for HER2-positive advanced gastric/gastroesophageal junction cancer.

    Product Name : HLX22

    Product Type : Antibody

    Upfront Cash : Inapplicable

    March 20, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Henlius Wins Orphan Drug Status for Anti-HER2 HLX22 in Gastric Cancer

    Details:

    HLX22 is a recombinant humanized Anti-HER2 mAb, being investigated in combination with SoC for HER2-positive advanced gastric/gastroesophageal junction cancer.


    Lead Product(s): HLX22,Oxaliplatin,Trastuzumab

    Therapeutic Area: Oncology Brand Name: HLX22

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 19, 2025

    blank

    07

    Shanghai Henlius Biotech

    China
    arrow
    Simposio AFI
    Not Confirmed

    Shanghai Henlius Biotech

    China
    arrow
    Simposio AFI
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : HLX22,Oxaliplatin,Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Henlius Wins Orphan Drug Status for Anti-HER2 HLX22 in Gastric Cancer

    Details : HLX22 is a recombinant humanized Anti-HER2 mAb, being investigated in combination with SoC for HER2-positive advanced gastric/gastroesophageal junction cancer.

    Product Name : HLX22

    Product Type : Antibody

    Upfront Cash : Inapplicable

    March 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    ALX Presents Updated Data from ASPEN-06 Phase 2 Trial in HER2-Positive Gastric Cancer

    Details:

    ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in combination with trastuzumab in patients with HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer.


    Lead Product(s): Evorpacept,Ramucirumab,Trastuzumab

    Therapeutic Area: Oncology Brand Name: ALX148

    Study Phase: Phase II/ Phase IIIProduct Type: Protein

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 23, 2025

    blank

    08

    ALX Oncology

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    ALX Oncology

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Evorpacept,Ramucirumab,Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    ALX Presents Updated Data from ASPEN-06 Phase 2 Trial in HER2-Positive Gastric Cancer

    Details : ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in combination with trastuzumab in patients with HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer.

    Product Name : ALX148

    Product Type : Protein

    Upfront Cash : Inapplicable

    January 23, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Alligator Doses First Patient in Shanghai Henlius Biotech Phase 3 Clinical Trial

    Details:

    HLX22 is a recombinant humanized Anti-HER2 mAb, being investigated in combination with SoC for HER2-positive advanced gastric/gastroesophageal junction cancer.


    Lead Product(s): HLX22,Oxaliplatin,Trastuzumab

    Therapeutic Area: Oncology Brand Name: HLX22

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Alligator Bioscience

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 04, 2024

    blank

    09

    Shanghai Henlius Biotech

    China
    arrow
    Simposio AFI
    Not Confirmed

    Shanghai Henlius Biotech

    China
    arrow
    Simposio AFI
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : HLX22,Oxaliplatin,Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Alligator Bioscience

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Alligator Doses First Patient in Shanghai Henlius Biotech Phase 3 Clinical Trial

    Details : HLX22 is a recombinant humanized Anti-HER2 mAb, being investigated in combination with SoC for HER2-positive advanced gastric/gastroesophageal junction cancer.

    Product Name : HLX22

    Product Type : Antibody

    Upfront Cash : Inapplicable

    December 04, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    BridgeBio Doses First Patient with BBO-10203 in Phase 1 BREAKER-101 Trial

    Details:

    BBO-10203 is a first-in-class orally bioavailable RAS:PI3Ka breaker that blocks the interaction between RAS and PI3Kα to inhibit PI3Kα-AKT signaling in tumors.


    Lead Product(s): BBO-10203,Trastuzumab

    Therapeutic Area: Oncology Brand Name: BBO-10203

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 30, 2024

    blank

    10

    BridgeBio Oncology Therapeutics

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    BridgeBio Oncology Therapeutics

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BBO-10203,Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    BridgeBio Doses First Patient with BBO-10203 in Phase 1 BREAKER-101 Trial

    Details : BBO-10203 is a first-in-class orally bioavailable RAS:PI3Ka breaker that blocks the interaction between RAS and PI3Kα to inhibit PI3Kα-AKT signaling in tumors.

    Product Name : BBO-10203

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Canada

    read-more
    read-more

    01

    AMGEN CANADA INC

    U.S.A
    FCE Pharma
    Not Confirmed
    arrow

    AMGEN CANADA INC

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    TRASTUZUMAB

    Brand Name : KANJINTI

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 150MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2518244

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Celltrion

    South Korea
    FCE Pharma
    Not Confirmed
    arrow

    Celltrion

    South Korea
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag South Korea
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    TRASTUZUMAB

    Brand Name : HERZUMA

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 150MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2506211

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Celltrion

    South Korea
    FCE Pharma
    Not Confirmed
    arrow

    Celltrion

    South Korea
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag South Korea
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    TRASTUZUMAB

    Brand Name : HERZUMA

    Dosage Form : KIT

    Dosage Strength : 440MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2480794

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    HOFFMANN-LA ROCHE LIMITED

    Switzerland
    FCE Pharma
    Not Confirmed
    arrow

    HOFFMANN-LA ROCHE LIMITED

    Switzerland
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    TRASTUZUMAB

    Brand Name : PERJETA-HERCEPTIN

    Dosage Form : SOLUTION

    Dosage Strength : 440MG/VIAL

    Packaging : 14ML & 20ML

    Approval Date :

    Application Number : 2405024

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    HOFFMANN-LA ROCHE LIMITED

    Switzerland
    FCE Pharma
    Not Confirmed
    arrow

    HOFFMANN-LA ROCHE LIMITED

    Switzerland
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    TRASTUZUMAB

    Brand Name : HERCEPTIN SC

    Dosage Form : SOLUTION

    Dosage Strength : 600MG/5ML

    Packaging :

    Approval Date :

    Application Number : 2480697

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    HOFFMANN-LA ROCHE LIMITED

    Switzerland
    FCE Pharma
    Not Confirmed
    arrow

    HOFFMANN-LA ROCHE LIMITED

    Switzerland
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    TRASTUZUMAB

    Brand Name : PHESGO

    Dosage Form : SOLUTION

    Dosage Strength : 40MG/ML

    Packaging :

    Approval Date :

    Application Number : 2512912

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    HOFFMANN-LA ROCHE LIMITED

    Switzerland
    FCE Pharma
    Not Confirmed
    arrow

    HOFFMANN-LA ROCHE LIMITED

    Switzerland
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    TRASTUZUMAB

    Brand Name : PHESGO

    Dosage Form : SOLUTION

    Dosage Strength : 60MG/ML

    Packaging :

    Approval Date :

    Application Number : 2512920

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    PFIZER CANADA ULC

    U.S.A
    FCE Pharma
    Not Confirmed
    arrow

    PFIZER CANADA ULC

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    TRASTUZUMAB

    Brand Name : TRAZIMERA

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 440MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2483467

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    PFIZER CANADA ULC

    U.S.A
    FCE Pharma
    Not Confirmed
    arrow

    PFIZER CANADA ULC

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    TRASTUZUMAB

    Brand Name : TRAZIMERA

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 150MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2483475

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    SAMSUNG BIOEPIS CO., LTD

    South Korea
    FCE Pharma
    Not Confirmed
    arrow

    SAMSUNG BIOEPIS CO., LTD

    South Korea
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag South Korea
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    TRASTUZUMAB

    Brand Name : ONTRUZANT

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 150MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2524317

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Solubilizers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Topical

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    STOCK RECAP #PipelineProspector

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search